Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | RGS12 | O14924 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10584810 | 1.00 | USP2 (0.54) | USP2PKMALOX15HIF1AHSD17B10 | |
| SCHEMBL29414373 | 1.00 | USP2 (0.54) | USP2PKMALOX15HIF1AHSD17B10 | |
| SCHEMBL44973 | 1.00 | USP2 (0.54) | USP2PKMALOX15HIF1AHSD17B10 | |
| SCHEMBL29430355 | 0.86 | USP2 (0.54) | USP2PKMALOX15HIF1AHSD17B10 | |
| SCHEMBL188143 | 0.86 | USP2 (0.54) | USP2PKMALOX15HIF1AHSD17B10 | |
| SCHEMBL188142 | 0.86 | USP2 (0.54) | USP2PKMALOX15HIF1AHSD17B10 | |
| SCHEMBL14271135 | 0.85 | DPP4 (0.48) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL751609 | 0.85 | USP2 (0.57) | USP2PKMALOX15HIF1AHSD17B10 | |
| SCHEMBL1577675 | 0.85 | USP2 (0.57) | USP2PKMALOX15HIF1AHSD17B10 | |
| SCHEMBL12375142 | 0.85 | USP2 (0.57) | USP2PKMALOX15HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 919 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| US-12612605-B2 | Carboxyesterase polypeptides for kinetic resolution | CODEXIS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260078417-A1 | TRANSAMINASE BIOCATALYSTS | CODEXIS, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | GENEFRONTIER CORPORATION (JP) | 2026-03-03 | — | — | US | disclosed |
| US-12565641-B2 | Engineered terminal deoxynucleotidyl transferase variants | CODEXIS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260043010-A1 | ENONE REDUCTASES | CODEXIS, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4687443-A1 | METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE | Genepep (FR) | 2026-02-11 | — | — | EP | disclosed |
| US-20260028600-A1 | TRANSAMINASE POLYPEPTIDES | CODEXIS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260022366-A1 | ENGINEERED NITROALDOLASES | CODEXIS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20030166138-A1 | Cyclic peptides and analogs useful to treat allergies | RIGEL PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | disclosed |
| US-20020177725-A1 | Peptide inhibitors of hepatitis C virus NS3 protein | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2002-11-28 | — | — | US | disclosed |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | disclosed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0720601-A1 | GASTRIN AND CCK RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1996-07-10 | — | — | EP | disclosed |
| WO-1995004720-A2 | GASTRIN AND CCK RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 1995-02-16 | — | — | WO | disclosed |
| US-4766110-A | INHIBITS ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVE AGENTS | RYAN JAMES W (US) | 1988-08-23 | — | — | US | disclosed |
| EP-0073143-B1 | NOVEL COMPLEX AMIDO AND IMIDO DERIVATIVES OF CARBOXYALKYL PEPTIDES AND THIOETHERS AND ETHERS OF PEPTIDES | Ryan, James Walter (US) | 1985-11-21 | — | — | EP | disclosed |
| EP-0048159-A2 | Novel carboxyalkyl peptides and thioethers and ethers of peptides as antihypertensive agents | UNIVERSITY OF MIAMI (US) | 1982-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022366-A1 | ENGINEERED NITROALDOLASES | NOS2, NOS1, NOS3 | USP2 1120/4885PKM 1070/4885ALOX15 2815/4885 |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | CXCL10, MLX, MICA | USP2 4057/4885PKM 3268/4885ALOX15 4783/4885 |
| US-12565641-B2 | Engineered terminal deoxynucleotidyl transferase variants | DNTT, RNGTT, POLM | USP2 3062/4885PKM 4382/4885ALOX15 4806/4885 |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | USP2 319/4885PKM 3002/4885ALOX15 764/4885 |
| US-20020177725-A1 | Peptide inhibitors of hepatitis C virus NS3 protein | VIP, PRSS1, SERPINB1 | USP2 867/4885PKM 3437/4885ALOX15 2917/4885 |
| US-12612605-B2 | Carboxyesterase polypeptides for kinetic resolution | CES1, CPA1, RNGTT | USP2 178/4885PKM 2702/4885ALOX15 2988/4885 |
| US-20260043010-A1 | ENONE REDUCTASES | DCXR, ENY2, UPF1 | USP2 1757/4885PKM 1448/4885ALOX15 3572/4885 |
| US-20260028600-A1 | TRANSAMINASE POLYPEPTIDES | GOT1, OAT, PEPD | USP2 1874/4885PKM 20/4885ALOX15 4256/4885 |
| US-20260078417-A1 | TRANSAMINASE BIOCATALYSTS | XDH, AGXT, PEPD | USP2 1031/4885PKM 392/4885ALOX15 3792/4885 |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | USP2 1504/4885PKM 4530/4885ALOX15 4675/4885 |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | CES1, CYP51A1, SPINT2 | USP2 633/4885PKM 606/4885ALOX15 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.